Systems medicine and the integration of bioinformatic tools for the diagnosis of Alzheimer's disease

Genome Medicine

Volumn 2, Issue 11, 2010, Pages

  Orešič, Matej ^a   Lötjönen, Jyrki ^a   Soininen, Hilkka ^b  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BIOINFORMATICS; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC TEST; DISEASE COURSE; HIGH THROUGHPUT SCREENING; HUMAN; MILD COGNITIVE IMPAIRMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 78751697294     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm204     Document Type: Review

References (58)

1. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002, 347:911-920. 10.1056/NEJMra020100, 12239261.
2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3:186-191. 10.1016/j.jalz.2007.04.381, 19595937.
3. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007, 20:380-385. 10.1097/YCO.0b013e32816ebc7b, 17551353.
4. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117. 10.1016/S0140-6736(05)67889-0, 2850264, 16360788.
5. Forstl H, Kurz A. Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999, 249:288-290. 10.1007/s004060050101, 10653284.
6. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ. Multiple cognitive deficits during the transition to Alzheimer's disease. J Intern Med 2004, 256:195-204. 10.1111/j.1365-2796.2004.01386.x, 15324363.
7. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1133-1142.
8. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B. Mild cognitive impairment. Lancet 2006, 367:1262-1270. 10.1016/S0140-6736(06)68542-5, 16631882.
9. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003, 84:1215-1236. 10.1046/j.1471-4159.2003.01615.x, 12614323.
10. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto L, Halonen P, Kontula K. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995, 333:1242-1247. 10.1056/NEJM199511093331902, 7566000.
11. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185. 10.1126/science.1566067, 1566067.
12. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002, 99:6364-6369. 10.1073/pnas.092136199, 122954, 11959919.
13. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands?. Trends Neurosci 2002, 25:22-26. 10.1016/S0166-2236(00)02031-2, 11801334.
14. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393. 10.1001/jama.2009.1064, 19622817.
15. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ, . for the Alzheimer's Disease Neuroimaging Initiative Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010, 67:949-956. 10.1001/archneurol.2010.179, 2963067, 20697045, for the Alzheimer's Disease Neuroimaging Initiative.
16. Marksteiner J, Hinterhuber H, Humpel C. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. Drugs Today (Barc) 2007, 43:423-431. 10.1358/dot.2007.43.6.1067341, 17612711.
17. Borroni B, Di Luca M, Padovani A. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?. Eur J Pharmacol 2006, 545:73-80. 10.1016/j.ejphar.2006.06.023, 16831417.
18. Tarawneh R, Holtzman DM. Biomarkers in translational research of Alzheimer's disease. Neuropharmacology 2010, 59:310-322. 10.1016/j.neuropharm.2010.04.006, 20394760.
19. Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. Neuroimage 2009, 47:1196-1206. 10.1016/j.neuroimage.2009.05.037, 2730171, 19463961.
20. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004, 4:309-314. 10.1038/nrc1322, 15057290.
21. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005, 5:142-149. 10.1038/nrc1550, 15685197.
22. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13:1359-1362. 10.1038/nm1653, 17934472.
23. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010, 67:1077-1081. 10.1001/archneurol.2010.215, 20837851.
24. Schipper HM, Maes OC, Chertkow HM, Wang E. MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio 2007, 1:263-274. 2759133, 19936094.
25. Maes OC, Xu S, Yu B, Chertkow HM, Wang E, Schipper HM. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 2007, 28:1795-1809. 10.1016/j.neurobiolaging.2006.08.004, 16979800.
26. Lenz EM, Bright J, Wilson ID, Hughes A, Morrisson J, Lindberg H, Lockton A. Metabonomics, dietary influences and cultural differences: a 1 H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J Pharm Biomed Anal 2004, 36:841-849. 10.1016/j.jpba.2004.08.002, 15533678.
27. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu PV, Yetukuri L, Islam S, Felin J, Perkins R, Boren J, Oresic M, Backhed F. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010, 51:1101-1112. 10.1194/jlr.M002774, 20040631.
28. Nikkilä J, Sysi-Aho M, Ermolov A, Seppänen-Laakso T, Simell O, Kaski S, Oresic M. Gender dependent progression of systemic metabolic states in early childhood. Mol Syst Biol 2008, 4:197. 10.1038/msb.2008.34, 2483410, 18523432.
29. Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, Prehn C, Altmaier E, Kastenmuller G, Kato BS, Mewes H-W, Meitinger T, de Angelis MH, Kronenberg F, Soranzo N, Wichmann H-E, Spector TD, Adamski J, Suhre K. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010, 42:137-141. 10.1038/ng.507, 20037589.
30. Oresic M, Vidal-Puig A, Hänninen V. Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev Mol Diagn 2006, 6:575-585. 10.1586/14737159.6.4.575, 16824031.
31. HUSERMET: Human Serum Metabolome in Health and Disease. , http://www.husermet.org/
32. PredictAD. , http://www.predictad.eu/
33. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008, 9:768-778. 10.1038/nrn2494, 18802446.
34. De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, Saez K, Henriquez JP, Zhao A, Wollmer MA, Nitsch RM, Hock C, Morris CM, Hardy J, Moon RT. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci USA 2007, 104:9434-9439. 10.1073/pnas.0603523104, 1890512, 17517621.
35. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528. 10.1126/science.1135308, 17185560.
36. Oresic M, Shalloway D. Specific correlations between relative synonymous codon usage and protein secondary structure. J Mol Biol 1998, 281:31-48. 10.1006/jmbi.1998.1921, 9680473.
37. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004, 6:1054-1061. 10.1038/ncb1104-1054, 15516999.
38. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008, 283:29615-29619. 10.1074/jbc.R800019200, 2573065, 18650430.
39. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, Nussinov R, Lal R. Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. Proc Natl Acad Sci USA 2010, 107:6538-6543. 10.1073/pnas.0914251107, 2851998, 20308552.
40. Brites P, Waterham HR, Wanders RJA. Functions and biosynthesis of plasmalogens in health and disease. Biochim Biophys Acta 2004, 1636:219-231.
41. Farooqu AA, Horrocks LA. Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue. J Mol Neurosci 2001, 16:263-272; discussion 279-284. 10.1385/JMN:16:2-3:263, 11478381.
42. Nagan N, Zoeller RA. Plasmalogens: biosynthesis and functions. Prog Lipid Res 2001, 40:199-229. 10.1016/S0163-7827(01)00003-0, 11275267.
43. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res 2007, 48:2485-2498. 10.1194/jlr.P700023-JLR200, 17664527.
44. Han X, Holtzman DM, McKeel DW. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 2001, 77:1168-1180. 10.1046/j.1471-4159.2001.00332.x, 11359882.
45. Farooqui AA, Rapoport SI, Horrocks LA. Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. Neurochem Res 1997, 22:523-527. 10.1023/A:1027380331807, 9130265.
46. Maeba R, Maeda T, Kinoshita M, Takao K, Takenaka H, Kusano J, Yoshimura N, Takeoka Y, Yasuda D, Okazaki T, Teramoto T. Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. J Atheroscler Thromb 2007, 14:12-18.
47. Su B, Wang X, Nunomura A, Moreira PI, Lee HG, Perry G, Smith MA, Zhu X. Oxidative stress signaling in Alzheimer's disease. Curr Alzheimer Res 2008, 5:525-532. 10.2174/156720508786898451, 2780015, 19075578.
48. Oresic M, Hanninen VA, Vidal-Puig A. Lipidomics: a new window to biomedical frontiers. Trends Biotechnol 2008, 26:647-652. 10.1016/j.tibtech.2008.09.001, 18951641.
49. Miller Y, Ma B, Nussinov R. Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape. Chem Rev 2010, 110:4820-4838. 10.1021/cr900377t, 2920034, 20402519.
50. Yu X, Wang J, Yang JC, Wang Q, Cheng SZ, Nussinov R, Zheng J. Atomic-scale simulations confirm that soluble beta-sheet-rich peptide self-assemblies provide amyloid mimics presenting similar conformational properties. Biophys J 2010, 98:27-36. 10.1016/j.bpj.2009.10.003, 20085717.
51. Niemelä PS, Ollila S, Hyvönen MT, Karttunen M, Vattulainen I. Assessing the nature of lipid raft membranes. PLoS Comput Biol 2007, 3:e34. 10.1371/journal.pcbi.0030034, 1808021, 17319738.
52. Yetukuri L, Söderlund S, Koivuniemi A, Seppänen-Laakso T, Niemelä PS, Hyvönen M, Taskinen MR, Vattulainen I, Jauhiainen M, Oresic M. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res 2010, 51:2341-2351. 10.1194/jlr.M006494, 20431113.
53. Searls DB. Data integration: challenges for drug discovery. Nat Rev Drug Discov 2005, 4:45-58. 10.1038/nrd1608, 15688072.
54. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006, 7:818-827. 10.1038/nrn1993, 16988657.
55. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, Mosedale DE, Kell DB, Barker RA, Grainger DJ, Rubinsztein DC. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006, 129:877-886. 10.1093/brain/awl027, 16464959.
56. Götz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 2004, 9:664-683.
57. Lotjonen JM, Wolz R, Koikkalainen JR, Thurfjell L, Waldemar G, Soininen H, Rueckert D. Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage 2010, 49:2352-2365. 10.1016/j.neuroimage.2009.10.026, 19857578.
58. ETHERPATHS. , http://www.etherpaths.org